文献速递冠心病心力衰竭与心肌病血脂与心血管预防

1999-2020年美国成人心血管、肾脏与代谢疾病共病患病率及重叠情况

Prevalence and Overlap of Cardiac, Renal, and Metabolic Conditions in US Adults, 1999-2020.
PubMed 文献 · JAMA Cardiol · 2023-01-01

该研究基于NHANES 2015-2020数据(n=11 607)及1999-2020趋势分析,发现26.3%美国成人至少患1种心血管-肾脏-代谢(CRM)疾病,8.0%患至少2种,1.5%患3种;CRM共病负担随时间显著增加,且治疗不足。

要点

  • 2015-2020年美国成人中26.3%有至少1种CRM疾病,8.0%有至少2种,1.5%有3种。
  • 65岁以上人群CRM共病负担更重:33.6%有1种、17.1%有2种、5.0%有3种。

核心结论

  • CRM共病在美国成人中日益常见且治疗不足,需协同综合管理策略。

研究设计与样本

  • 队列研究,采用2015年1月至2020年3月NHANES全国代表性横断面数据评估现患率,并比较1999-2002与2015-2020数据评估趋势。
  • 纳入11 607名非妊娠美国成人(≥20岁),平均(SE)年龄48.5(0.4)岁,女性占51.0%。

主要发现

  • 2015-2020年,26.3%至少1种CRM疾病,8.0%至少2种,1.5%有3种。
  • 最常见的CRM二联为CKD+T2D(3.2%),其次CVD+T2D(1.7%)和CVD+CKD(1.6%)。
  • ≥65岁人群中,33.6%有1种、17.1%有2种、5.0%有3种CRM疾病;CKD+T2D(7.3%)最常见,其次CVD+CKD(6.0%)和CVD+T2D(3.8%)。
  • CRM共病负担在非西班牙裔黑人、失业、低社会经济地位及无高中学历者中不成比例地高。
  • 3种CRM疾病患者中,30.5%未报告他汀使用,仅4.8%和3.0%分别使用GLP-1受体激动剂和SGLT2抑制剂。

临床怎么用

  • 对CRM共病患者应评估共病重叠情况,尤其高龄、男性及弱势人群。
  • 应关注他汀、GLP-1受体激动剂和SGLT2抑制剂在CRM共病人群中的使用不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Individually, cardiac, renal, and metabolic (CRM) conditions are common and leading causes of death, disability, and health care-associated costs. However, the frequency with which CRM conditions coexist has not been comprehensively characterized to date. OBJECTIVE: To examine the prevalence and overlap of CRM conditions among US adults currently and over time. DESIGN, SETTING, AND PARTICIPANTS: To establish prevalence of CRM conditions, nationally representative, serial cross-sectional data included in the January 2015 through March 2020 National Health and Nutrition Examination Survey (NHANES) were evaluated in this cohort study. To assess temporal trends in CRM overlap, NHANES data between 1999-2002 and 2015-2020 were compared. Data on 11 607 nonpregnant US adults (≥20 years) were included. Data analysis occurred between November 10, 2020, and November 23, 2022. MAIN OUTCOMES AND MEASURES: Proportion of participants with CRM conditions, overall and stratified by age, defined as cardiovascular disease (CVD), chronic kidney disease (CKD), type 2 diabetes (T2D), or all 3. RESULTS: From 2015 through March 2020, of 11 607 US adults included in the analysis (mean [SE] age, 48.5 [0.4] years; 51.0% women), 26.3% had at least 1 CRM condition, 8.0% had at least 2 CRM conditions, and 1.5% had 3 CRM conditions. Overall, CKD plus T2D was the most common CRM dyad (3.2%), followed by CVD plus T2D (1.7%) and CVD plus CKD (1.6%). Participants with higher CRM comorbidity burden were more likely to be older and male. Among participants aged 65 years or older, 33.6% had 1 CRM condition, 17.1% had 2 CRM conditions, and 5.0% had 3 CRM conditions. Within this subset, CKD plus T2D (7.3%) was most common, followed by CVD plus CKD (6.0%) and CVD plus T2D (3.8%). The CRM comorbidity burden was disproportionately high among participants reporting non-Hispanic Black race or ethnicity, unemployment, low socioeconomic status, and no high school degree. Among participants with 3 CRM conditions, nearly one-third (30.5%) did not report statin use, and only 4.8% and 3.0% used glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors, respectively. Between 1999 and 2020, the proportion of US adults with multiple CRM conditions increased significantly (from 5.3% to 8.0%; P < .001 for trend), as did the proportion having all 3 CRM conditions (0.7% to 1.5%; P < .001 for trend). CONCLUSIONS AND RELEVANCE: This cohort study found that CRM multimorbidity is increasingly common and undertreated among US adults, highlighting the importance of collaborative and comprehensive management strategies.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Ostrominski JW, Arnold SV, Butler J, et al. Prevalence and Overlap of Cardiac, Renal, and Metabolic Conditions in US Adults, 1999-2020. JAMA Cardiol. 2023. PMID: 37755728. doi:10.1001/jamacardio.2023.3241

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。